Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
| العنوان: | Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis |
|---|---|
| المؤلفون: | Hernandez-Boluda, JC, Pastor-Galan, I, Arellano-Rodrigo, E, Raya, JM, Perez-Encinas, M, Ayala, R, Ferrer-Marin, F, Velez, P, Mora, E, Fox, ML, Hernandez-Rivas, JM, Xicoy, B, Mata-Vazquez, MI, Garcia-Fortes, M, Perez-Lopez, R, Angona, A, Cuevas, B, Senin, A, Ramirez, MJ, Ramirez-Payer, A, Gomez-Casares, MT, Martinez-Valverde, C, Magro, E, Steegmann, JL, Duran, MA, Garcia-Hernandez, C, Gasior, M, de Villambrosia, SG, Alvarez-Larran, A, Pereira, A |
| المصدر: | BRITISH JOURNAL OF HAEMATOLOGY r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau British Journal of Haematology r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol |
| بيانات النشر: | WILEY, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | treatment, Primary Myelofibrosis, Risk Factors, Humans, Thrombosis, Hemorrhage, myelofibrosis, Hematology, Registries, bleeding, thrombosis, Thrombocythemia, Essential |
| الوصف: | Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in 1613 patients from the Spanish Myelofibrosis Registry. Over a total of 6981 patient-years at risk, 6.4% of the study population had at least one thrombotic event after MF diagnosis, amounting to an incidence rate of 1.65 per 100 patient-years. Prior history of thrombosis, the JAK2 mutation, and the intermediate-2/high-risk International Prognostic Scoring System (IPSS) categories conferred an increased thrombotic risk after adjustment for the risk-modifying effect of anti-thrombotic and cytoreductive treatments. History of thrombosis and the JAK2 mutation allowed us to pinpoint a group of patients at higher risk of early thrombosis. No decreased incidence of thrombosis was observed while patients were on anti-thrombotic or cytoreductive treatment. An increased risk of venous thrombosis was found during treatment with immunomodulatory agents. A total of 5.3% of patients had at least one episode of major bleeding, resulting in an incidence rate of 1.5 events per 100 patient-years. Patients in the intermediate-2/high-risk IPSS categories treated with anti-coagulants had an almost sevenfold increased risk of major bleeding. These findings should prove useful for guiding decision-making in clinical practice. |
| تدمد: | 0007-1048 1365-2141 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0211736ec059ba75fce35712e1744cc https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16898 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....c0211736ec059ba75fce35712e1744cc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00071048 13652141 |
|---|